Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RMC-5127

Small molecule · Inhibitor of KRAS G12V mutant protein (GTP-bound ON form) (KRAS) · developed by Revolution Medicines

Phase 1 Most advanced trial
RVMD Developer
1 Registered trials

What is RMC-5127?

RMC-5127 is an orally bioavailable, non-covalent inhibitor of the active GTP-bound form of the KRAS G12V mutant protein. It binds cyclophilin A to form a tri-complex that sterically blocks downstream effector binding, and it is studied in non-small cell lung cancer, colorectal cancer, and pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
KRAS G12V mutant protein (GTP-bound ON form) (KRAS), cyclophilin A (PPIA) (binding partner it blocks)
Mechanism
Inhibitor of KRAS G12V mutant protein (GTP-bound ON form) (KRAS)
Pathways
RAS/downstream effector signaling, interferon signaling, MHC class I antigen presentation, tumor immune evasion
Therapy area
Oncology
Developer
Revolution Medicines, Inc. (RVMD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07349537 Phase 1 Non-small Cell Lung Cancer (NSCLC) Recruiting RVMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsColorectal Cancer (CRC)CRCLung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)NSCLCPancreatic AdenocarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)PDAC

Other drugs acting on KRAS

More from Revolution Medicines

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RVMD page.

Follow RVMD, the company behind RMC-5127

See RVMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RVMD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.